Aptamer-engaged nanotherapeutics against SARS-CoV-2
Source abstract
Abstract
The COVID-19 pandemic, caused by the virus SARS-CoV-2 infection, has underscored the critical importance of rapid and accurate therapeutics. The neutralization of SARS-CoV-2 is paramount in controlling the spread and impact of COVID-19. In this context, the integration of aptamers and aptamer-related nanotherapeutics presents a valuable and scientifically significant approach. Despite the potential, current reviews in this area are often not comprehensive and specific enough to encapsulate the full scope of therapeutic principles, strategies, advancements, and challenges. This review aims to fill that gap by providing an in-depth examination of the role of aptamers and their related molecular medicine in COVID-19 therapeutics. We first introduce the unique properties, selection, and recognition mechanism of aptamers to bind with high affinity to various targets. Next, we delve into the therapeutic potential of aptamers, focusing on their ability to inhibit viral entry and replication, as well as modulate the host immune response. The integration of aptamers with nucleic acid nanomedicine is explored. Finally, we address the challenges and future perspectives of aptamer and nucleic acid nanomedicine in COVID-19 therapeutics, including issues of stability, delivery, and manufacturing scalability. We conclude by underscoring the importance of continued research and development in this field to meet the ongoing challenges posed by COVID-19 and potential future pandemics. Our review will be a valuable resource for researchers and clinicians interested in the latest developments at the intersection of molecular biology, nanotechnology, and infectious disease management.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · SARS-CoV-2 detection and testing · SARS-CoV-2 and COVID-19 Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Grantz KH, Meredith HR, Cummings DAT, Metcalf CJE, Grenfell BT, Giles JR, et al. The Use of Mobile Phone Data to Inform Analysis of COVID-19 Pandemic Epidemiology. Nat Commun. 2020;11(1):4961. https://doi.org/10.1038/s41467-020-18190-5.10.1038/s41467-020-18190-5 ↗
2. Bhagat S, Yadav N, Shah J, Dave H, Swaraj S, Tripathi S, et al. Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. Expert Rev Anti Infect Ther. 2022;20(10):1275–98. https://doi.org/10.1080/14787210.2021.1835469.10.1080/14787210.2021.1835469 ↗
3. Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85–100. https://doi.org/10.1016/j.biochi.2020.09.018.10.1016/j.biochi.2020.09.018 ↗
4. Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol Genomics. 2020;52(11):549–57. https://doi.org/10.1152/physiolgenomics.00089.2020.10.1152/physiolgenomics.00089.2020 ↗
5. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3. https://doi.org/10.1038/s41586-020-2012-7.10.1038/s41586-020-2012-7 ↗
6. Kang S, Yang M, Hong Z, Zhang L, Huang Z, Chen X, et al. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B. 2020;10(7):1228–38. https://doi.org/10.1016/j.apsb.2020.04.009.10.1016/j.apsb.2020.04.009 ↗
7. Zhang Q, Xiang R, Huo S, Zhou Y, Jiang S, Wang Q, et al. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct Target Ther. 2021;6(1):233. https://doi.org/10.1038/s41392-021-00653-w.10.1038/s41392-021-00653-w ↗
8. Hingrat QL, Visseaux B, Laouenan C, Tubiana S, Bouadma L, Yazdanpanah Y, et al. Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives. Clin Microbiol Infect. 2020;27(5):789 e1-5. https://doi.org/10.1016/j.cmi.2020.11.025.10.1016/j.cmi.2020.11.025 ↗
9. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–20. https://doi.org/10.1038/s41586-020-2180-5.10.1038/s41586-020-2180-5 ↗
10. Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117(21):11727–34. https://doi.org/10.1073/pnas.2003138117.10.1073/pnas.2003138117 ↗
11. Lin Q, Wen D, Wu J, Liu L, Wu W, Fang X, et al. Microfluidic immunoassays for sensitive and simultaneous detection of IgG/IgM/Antigen of SARS-CoV-2 within 15 min. Anal Chem. 2020;92(14):9454–8. https://doi.org/10.1021/acs.analchem.0c01635.10.1021/acs.analchem.0c01635 ↗
12. Tang J, Li J, Li G, Zhang H, Wang L, Li D, et al. Spermidine-mediated poly(lactic-co-glycolic acid) nanoparticles containing fluorofenidone for the treatment of idiopathic pulmonary fibrosis. Int J Nanomed. 2017;12:6687–704. https://doi.org/10.2147/IJN.S140569.10.2147/IJN.S140569 ↗
13. Feng X, Ma Z, Yu C, Xin R. MRNDR: multihead attention-based recommendation network for drug repurposing. J Chem Inf Model. 2024;64(7):2654–69. https://doi.org/10.1021/acs.jcim.3c01726.10.1021/acs.jcim.3c01726 ↗
14. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of covid-19—final report. N Engl J Med. 2020;383(19):1813–26. https://doi.org/10.1056/NEJMoa2007764.10.1056/NEJMoa2007764 ↗
15. Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (panoramic): an open-label, platform-adaptive randomised controlled trial. The Lancet. 2023;401(10373):281–93. https://doi.org/10.1016/S0140-6736(22)02597-1.10.1016/S0140-6736(22)02597-1 ↗
16. Toussi SS, Hammond JL, Gerstenberger BS, Anderson AS. Therapeutics for COVID-19. Nat Microbiol. 2023;8(5):771–86. https://doi.org/10.1038/s41564-023-01356-4.10.1038/s41564-023-01356-4 ↗
17. Parashar NC, Poddar J, Chakrabarti S, Parashar G. Repurposing of SARS-CoV nucleocapsid protein specific nuclease resistant RNA aptamer for therapeutics against SARS-CoV-2. Infect Genet Evol. 2020;85: 104497. https://doi.org/10.1016/j.meegid.2020.104497.10.1016/j.meegid.2020.104497 ↗
18. Lin B, Xiao F, Jiang J, Zhao Z, Zhou X. Engineered aptamers for molecular imaging. Chem Sci. 2023;14(48):14039–61. https://doi.org/10.1039/d3sc03989g.10.1039/d3sc03989g ↗
19. Bohrmann L, Burghardt T, Haynes C, Saatchi K, Hafeli UO. Aptamers used for molecular imaging and theranostics-recent developments. Theranostics. 2022;12(9):4010–50. https://doi.org/10.7150/thno.72949.10.7150/thno.72949 ↗
20. Strauss S, Nickels PC, Strauss MT, Jimenez Sabinina V, Ellenberg J, Carter JD, et al. Modified aptamers enable quantitative sub-10-nm cellular DNA-paint imaging. Nat Methods. 2018;15(9):685–8. https://doi.org/10.1038/s41592-018-0105-0.10.1038/s41592-018-0105-0 ↗
21. Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2017;16(3):181–202. https://doi.org/10.1038/nrd.2016.199.10.1038/nrd.2016.199 ↗
22. Huang M, Yang J, Wang T, Song J, Xia J, Wu L, et al. Homogeneous, low-volume, efficient, and sensitive quantitation of circulating exosomal PD-L1 for cancer diagnosis and immunotherapy response prediction. Angew Chem Int Ed Engl. 2020;59(12):4800–5. https://doi.org/10.1002/anie.201916039.10.1002/anie.201916039 ↗
23. Ren M, Wang Y, Luo Y, Yao X, Yang Z, Zhang P, et al. Functionalized nanoparticles in prevention and targeted therapy of viral diseases with neurotropism properties, special insight on COVID-19. Front Microbiol. 2021;12: 767104. https://doi.org/10.3389/fmicb.2021.767104.10.3389/fmicb.2021.767104 ↗
24. Liu M, Yu X, Chen Z, Yang T, Yang D, Liu Q, et al. Aptamer selection and applications for breast cancer diagnostics and therapy. J Nanobiotechnol. 2017;15(1):81. https://doi.org/10.1186/s12951-017-0311-4.10.1186/s12951-017-0311-4 ↗
25. Wandtke T, Wędrowska E, Szczur M, Przybylski G, Libura M, Kopiński P. Aptamers-diagnostic and therapeutic solution in SARS-CoV-2. Int J Mol Sci. 2022;23(3):1412. https://doi.org/10.3390/ijms23031412.10.3390/ijms23031412 ↗
26. Wang D, Li S, Zhao Z, Zhang X, Tan W. Engineering a second-order DNA logic-gated nanorobot to sense and release on live cell membranes for multiplexed diagnosis and synergistic therapy. Angew Chem Int Ed. 2021;60(29):15816–20. https://doi.org/10.1002/anie.202103993.10.1002/anie.202103993 ↗
27. Wang D, Peng R, Peng Y, Deng Z, Xu F, Su Y, et al. Hierarchical fabrication of DNA wireframe nanoarchitectures for efficient cancer imaging and targeted therapy. ACS Nano. 2020;14(12):17365–75. https://doi.org/10.1021/acsnano.0c07495.10.1021/acsnano.0c07495 ↗
28. Wang D, Zhang J, Huang Z, Yang Y, Fu T, Yang Y, et al. Robust covalent aptamer strategy enables sensitive detection and enhanced inhibition of SARS-CoV-2 proteins. ACS Cent Sci. 2023;9(1):72–83. https://doi.org/10.1021/acscentsci.2c01263.10.1021/acscentsci.2c01263 ↗
29. Li L, Li M. Modular engineering of aptamer-based nanobiotechnology for conditional control of ATP sensing. Adv Mater. 2024;36(22): e2302972. https://doi.org/10.1002/adma.202302972.10.1002/adma.202302972 ↗
30. Guo L, Zhang Y, Wang Y, Xie M, Dai J, Qu Z, et al. Directing multivalent aptamer-receptor binding on the cell surface with programmable atom-like nanoparticles. Angew Chem Int Ed. 2022;61(18): e202117168. https://doi.org/10.1002/anie.202117168.10.1002/anie.202117168 ↗
31. Mao M, Lin Z, Chen L, Zou Z, Zhang J, Dou Q, et al. Modular DNA-origami-based nanoarrays enhance cell binding affinity through the “lock-and-key” interaction. J Am Chem Soc. 2023;145(9):5447–55. https://doi.org/10.1021/jacs.2c13825.10.1021/jacs.2c13825 ↗
32. Xiang Z, Zhao J, Yi D, Di Z, Li L. Peptide nucleic acid (PNA)-guided peptide engineering of an aptamer sensor for protease-triggered molecular imaging. Angew Chem Int Ed. 2021;60(42):22659–63. https://doi.org/10.1002/anie.202106639.10.1002/anie.202106639 ↗
33. Maganzini N, Thompson I, Wilson B, Soh HT. Pre-equilibrium biosensors as an approach towards rapid and continuous molecular measurements. Nat Commun. 2022;13(1):7072. https://doi.org/10.1038/s41467-022-34778-5.10.1038/s41467-022-34778-5 ↗
34. Ouyang Y, O’Hagan MP, Willner B, Willner I. Aptamer-modified homogeneous catalysts, heterogenous nanoparticle catalysts, and photocatalysts: functional “nucleoapzymes”, “aptananozymes”, and “photoaptazymes.” Adv Mater. 2024;36(10): e2210885. https://doi.org/10.1002/adma.202210885.10.1002/adma.202210885 ↗
35. Brown TM, Fakih HH, Saliba D, Asohan J, Sleiman HF. Stabilization of functional DNA structures with mild photochemical methods. J Am Chem Soc. 2023;145(4):2142–51. https://doi.org/10.1021/jacs.2c08808.10.1021/jacs.2c08808 ↗
36. Banik M, Ledray AP, Wu Y, Lu Y. Delivering DNA aptamers across the blood-brain barrier reveals heterogeneous decreased ATP in different brain regions of Alzheimer’s disease mouse models. ACS Cent Sci. 2024;10(8):1585–93. https://doi.org/10.1021/acscentsci.4c00563.10.1021/acscentsci.4c00563 ↗
37. Chauhan N, Xiong Y, Ren S, Dwivedy A, Magazine N, Zhou L, et al. Net-shaped DNA nanostructures designed for rapid/sensitive detection and potential inhibition of the SARS-CoV-2 virus. J Am Chem Soc. 2023;145(37):20214–28. https://doi.org/10.1021/jacs.2c04835.10.1021/jacs.2c04835 ↗
38. Chen J, Xu S, Ye Q, Chi H, Li Y, Wu M, et al. A topology-matching spike protein-capping tetrahedral DNA nanocrown for SARS-CoV-2 neutralization. CCS Chemistry. 2023;5(6):1372–85. https://doi.org/10.31635/ccschem.022.202201945.10.31635/ccschem.022.202201945 ↗
39. Wan S, Liu S, Sun M, Zhang J, Wei X, Song T, et al. Spatial- and valence-matched neutralizing DNA nanostructure blocks wild-type SARS-CoV-2 and omicron variant infection. ACS Nano. 2022;16(9):15310–7. https://doi.org/10.1021/acsnano.2c06803.10.1021/acsnano.2c06803 ↗
40. Zhang J, Xu Y, Chen M, Huang Y, Song T, Yang C, et al. Elucidating the effect of nanoscale receptor-binding domain organization on SARS-CoV-2 infection and immunity activation with DNA origami. J Am Chem Soc. 2022;144(46):21295–303. https://doi.org/10.1021/jacs.2c09229.10.1021/jacs.2c09229 ↗
41. Zhang J, Xu Y, Chen M, Wang S, Lin G, Huang Y, et al. Spatial engineering of heterotypic antigens on a DNA framework for the preparation of mosaic nanoparticle vaccines with enhanced immune activation against SARS-CoV-2 variants. Angew Chem Int Ed Engl. 2024;63(46): e202412294. https://doi.org/10.1002/anie.202412294.10.1002/anie.202412294 ↗
42. Pallavi P, Harini K, Elboughdiri N, Gowtham P, Girigoswami A, Girigoswami K. Infections associated with SARS-CoV-2 exploited via nanoformulated photodynamic therapy. ADMET and DMPK. 2023;11(4):513–31. https://doi.org/10.5599/admet.1883.10.5599/admet.1883 ↗
43. Atchaya J, Girigoswami A, Girigoswami K. Versatile applications of nanosponges in biomedical field: a glimpse on SARS-CoV-2 management. BioNanoScience. 2022;12(3):1018–31. https://doi.org/10.1007/s12668-022-01000-1.10.1007/s12668-022-01000-1 ↗
44. Thirumalai A, Harini K, Pallavi P, Gowtham P, Girigoswami K, Girigoswami A. Bile salt-mediated surface-engineered bilosome-nanocarriers for delivering therapeutics. Nanomed J. 2024;11(1):1–12. https://doi.org/10.22038/nmj.2023.71268.1763.10.22038/nmj.2023.71268.1763 ↗
45. Govindharaj P, Karthick H, Pallavi P, Gowtham P, Girigoswami K, Girigoswami A. RNA-a choice of potential drug delivery system. Int J Polym Mater Polym Biomater. 2022;72:1–15. https://doi.org/10.1080/00914037.2022.2058946.10.1080/00914037.2022.2058946 ↗
46. Dong Y, Wang J, Chen L, Chen H, Dang S, Li F. Aptamer-based assembly systems for SARS-CoV-2 detection and therapeutics. Chem Soc Rev. 2024;53(13):6830–59. https://doi.org/10.1039/d3cs00774j.10.1039/d3cs00774j ↗
47. Dzuvor CKO, Tettey EL, Danquah MK. Aptamers as promising nanotheranostic tools in the COVID-19 pandemic era. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022;14(3): e1785. https://doi.org/10.1002/wnan.1785.10.1002/wnan.1785 ↗
48. Zhang W, Liu N, Zhang J. Functional nucleic acids as modular components against SARS-CoV-2: from diagnosis to therapeutics. Biosens Bioelectron. 2022;201: 113944. https://doi.org/10.1016/j.bios.2021.113944.10.1016/j.bios.2021.113944 ↗
49. Amini R, Zhang Z, Li J, Gu J, Brennan JD, Li Y. Aptamers for SARS-CoV-2: isolation, characterization, and diagnostic and therapeutic developments. Anal Sens. 2022;2(5): e202200012. https://doi.org/10.1002/anse.202200012.10.1002/anse.202200012 ↗
50. Lou B, Liu Y, Shi M, Chen J, Li K, Tan Y, et al. Aptamer-based biosensors for virus protein detection. Trends Anal Chem. 2022;157: 116738. https://doi.org/10.1016/j.trac.2022.116738.10.1016/j.trac.2022.116738 ↗
51. Zhang Y, Juhas M, Kwok CK. Aptamers targeting SARS-CoV-2: a promising tool to fight against COVID-19. Trends Biotechnol. 2023;41(4):528–44. https://doi.org/10.1016/j.tibtech.2022.07.012.10.1016/j.tibtech.2022.07.012 ↗
52. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A. 2006;103(32):11838–43. https://doi.org/10.1073/pnas.0602615103.10.1073/pnas.0602615103 ↗
53. Xu G, Zhao J, Liu N, Yang M, Zhao Q, Li C, et al. Structure-guided post-SELEX optimization of an ochratoxin a aptamer. Nucleic Acids Res. 2019;47(11):5963–72. https://doi.org/10.1093/nar/gkz336.10.1093/nar/gkz336 ↗
54. Qi S, Duan N, Khan IM, Dong X, Zhang Y, Wu S, et al. Strategies to manipulate the performance of aptamers in SELEX, post-SELEX and microenvironment. Biotechnol Adv. 2022;55: 107902. https://doi.org/10.1016/j.biotechadv.2021.107902.10.1016/j.biotechadv.2021.107902 ↗
55. Vibhute MA, Machatzke C, Bigler K, Krümpel S, Summerer D, Mutschler H. Intracellular expression of a fluorogenic DNA aptamer using Retron Eco2. bioRxiv. 2024. https://doi.org/10.1101/2024.05.21.595248.10.1101/2024.05.21.595248 ↗
56. Dunn MR, Jimenez RM, Chaput JC. Analysis of aptamer discovery and technology. Nat Rev Chem. 2017;1(10):0076. https://doi.org/10.1038/s41570-017-0076.10.1038/s41570-017-0076 ↗
57. Shraim AS, Abdel Majeed BA, Al-Binni MA, Hunaiti A. Therapeutic potential of aptamer-protein interactions. ACS Pharmacol Transl Sci. 2022;5(12):1211–27. https://doi.org/10.1021/acsptsci.2c00156.10.1021/acsptsci.2c00156 ↗
58. Liu X, Wang YL, Wu J, Qi J, Zeng Z, Wan Q, et al. Neutralizing aptamers block S/RBD-ACE2 interactions and prevent host cell infection. Angew Chem Int Ed Engl. 2021;60(18):10273–8. https://doi.org/10.1002/anie.202100345.10.1002/anie.202100345 ↗
59. Ishizuka T, Yamashita A, Asada Y, Xu Y. Studying DNA G-quadruplex aptamer by 19F NMR. ACS Omega. 2017;2(12):8843–8. https://doi.org/10.1021/acsomega.7b01405.10.1021/acsomega.7b01405 ↗
60. Sun M, Liu S, Wei X, Wan S, Huang M, Song T, et al. Aptamer blocking strategy inhibits SARS-CoV-2 virus infection. Angew Chem Int Ed Engl. 2021;60(18):10266–72. https://doi.org/10.1002/anie.202100225.10.1002/anie.202100225 ↗
61. Zichen Q, Zhu Y, Xiang Y. Covalent bonding aptamer with enhanced SARS-CoV-2 RBD-ACE2 blocking and pseudovirus neutralization activities. 2021. Available from: https://doi.org/10.33774/chemrxiv-2021-nd0r2-v2.10.33774/chemrxiv-2021-nd0r2-v2 ↗
62. Valero J, Civit L, Dupont DM, Selnihhin D, Reinert LS, Idorn M, et al. A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. Proc Natl Acad Sci U S A. 2021;118(50): e2112942118. https://doi.org/10.1073/pnas.2112942118.10.1073/pnas.2112942118 ↗
63. Schmitz A, Weber A, Bayin M, Breuers S, Fieberg V, Famulok M, et al. A SARS-CoV-2 spike binding DNA aptamer that inhibits pseudovirus infection by an RBD-independent mechanism. Angew Chem Int Ed Engl. 2021;60(18):10279–85. https://doi.org/10.1002/anie.202100316.10.1002/anie.202100316 ↗
64. Silwal AP, Thennakoon SKS, Arya SP, Postema RM, Jahan R, Phuoc CMT, et al. DNA aptamers inhibit SARS-CoV-2 spike-protein binding to hACE2 by an RBD-independent or dependent approach. Theranostics. 2022;12(12):5522–36. https://doi.org/10.7150/thno.74428.10.7150/thno.74428 ↗
65. Li W, Xu S, Li Y, Chen J, Ma Y, Liu Z. High mannose-specific aptamers for broad-spectrum virus inhibition and cancer targeting. CCS Chemistry. 2023;5(2):497–509. https://doi.org/10.31635/ccschem.022.202101747.10.31635/ccschem.022.202101747 ↗
66. Yang G, Zhang S, Wang Y, Li L, Li Y, Yuan D, et al. Aptamer blocking S-Tlr4 interaction selectively inhibits SARS-CoV-2 induced inflammation. Signal Transduct Target Ther. 2022;7(1):120. https://doi.org/10.1038/s41392-022-00968-2.10.1038/s41392-022-00968-2 ↗
67. Yang G, Zhang S, Song W, Bai X, Li L, Luo F, et al. Efficient targeted delivery of bifunctional circular aptamer-ASO chimera to suppress the SARS-CoV-2 proliferation and inflammation. Small. 2023;19(16): e2207066. https://doi.org/10.1002/smll.202207066.10.1002/smll.202207066 ↗
68. Saify Nabiabad H, Amini M, Demirdas S. Specific delivering of RNAi using spike’s aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: a strong anti-covid drug in a clinical case study. Chem Biol Drug Des. 2022;99(2):233–46. https://doi.org/10.1111/cbdd.13978.10.1111/cbdd.13978 ↗
69. Yang G, Li Z, Mohammed I, Zhao L, Wei W, Xiao H, et al. Identification of SARS-CoV-2-against aptamer with high neutralization activity by blocking the RBD domain of spike protein 1. Signal Transduct Target Ther. 2021;6(1):227. https://doi.org/10.1038/s41392-021-00649-6.10.1038/s41392-021-00649-6 ↗
70. Silwal AP, Jahan R, Thennakoon SKS, Arya SP, Postema RM, Vander Ark EC, et al. A universal DNA aptamer as an efficient inhibitor against spike-protein/hACE2 interactions. Chem Commun (Camb). 2022;58(58):8049–52. https://doi.org/10.1039/d2cc02647c.10.1039/d2cc02647c ↗
71. Gelinas AD, Tan TK, Liu S, Jaramillo JG, Chadwick J, Harding AC, et al. Broadly neutralizing aptamers to SARS-CoV-2: a diverse panel of modified DNA antiviral agents. Mol Ther Nucleic Acids. 2023;31:370–82. https://doi.org/10.1016/j.omtn.2023.01.008.10.1016/j.omtn.2023.01.008 ↗
72. Peinetti AS, Lake RJ, Cong W, Cooper L, Wu Y, Ma Y, et al. Direct detection of human adenovirus or SARS-CoV-2 with ability to inform infectivity using DNA aptamer-nanopore sensors. Sci Adv. 2021;7(39):eabh2848. https://doi.org/10.1126/sciadv.abh2848.10.1126/sciadv.abh2848 ↗
73. Morena F, Argentati C, Tortorella I, Emiliani C, Martino S. De novo ssRNA aptamers against the SARS-CoV-2 main protease: in silico design and molecular dynamics simulation. Int J Mol Sci. 2021;22(13):6874. https://doi.org/10.3390/ijms22136874.10.3390/ijms22136874 ↗
74. Haberland A, Krylova O, Nikolenko H, Göttel P, Dallmann A, Müller J, et al. Aptamer BC 007’s affinity to specific and less-specific anti-SARS-CoV-2 neutralizing antibodies. Viruses. 2021;13(5):932. https://doi.org/10.3390/v13050932.10.3390/v13050932 ↗
75. Weisshoff H, Krylova O, Nikolenko H, Dungen HD, Dallmann A, Becker S, et al. Aptamer BC 007—efficient binder of spreading-crucial SARS-CoV-2 proteins. Heliyon. 2020;6(11): e05421. https://doi.org/10.1016/j.heliyon.2020.e05421.10.1016/j.heliyon.2020.e05421 ↗
76. Kim W, Song ES, Lee SH, Yang SH, Cho J, Kim SJ. A new DNA aptamer which binds to SARS-CoV-2 spike protein and reduces pro-inflammatory response. Sci Rep. 2024;14(1):7516. https://doi.org/10.1038/s41598-024-58315-0.10.1038/s41598-024-58315-0 ↗
77. Huang Y, Huang C, Chen J, Chen S, Li B, Li J, et al. Inhibition of SARS-CoV-2 replication by a ssDNA aptamer targeting the nucleocapsid protein. Microbiol Spectr. 2024;12(4): e0341023. https://doi.org/10.1128/spectrum.03410-23.10.1128/spectrum.03410-23 ↗
78. Li H, Zhou Y, Zhang M, Wang H, Zhao Q, Liu J. Updated approaches against SARS-CoV-2. Antimicrob Agents Chemother. 2020;64(6):10–128. https://doi.org/10.1128/aac.00483-20.10.1128/aac.00483-20 ↗
79. Zhang M, Ye L. Detection of SARS-CoV-2 receptor binding domain using fluorescence probe and DNA flowers enabled by rolling circle amplification. Microchim Acta. 2023;190(4):163. https://doi.org/10.1007/s00604-023-05747-6.10.1007/s00604-023-05747-6 ↗
80. Sun M, Liu S, Song T, Chen F, Zhang J, Huang JA, et al. Spherical neutralizing aptamer inhibits SARS-CoV-2 infection and suppresses mutational escape. J Am Chem Soc. 2021;143(51):21541–8. https://doi.org/10.1021/jacs.1c08226.10.1021/jacs.1c08226 ↗
81. Sun M, Wu Z, Zhang J, Chen M, Lu Y, Yang C, et al. Spherical neutralizing aptamer suppresses SARS-CoV-2 omicron escape. Nano Today. 2022;44: 101499. https://doi.org/10.1016/j.nantod.2022.101499.10.1016/j.nantod.2022.101499 ↗
82. Zhang J, Xu Y, Huang Y, Sun M, Liu S, Wan S, et al. Spatially patterned neutralizing icosahedral DNA nanocage for efficient SARS-CoV-2 blocking. J Am Chem Soc. 2022;144(29):13146–53. https://doi.org/10.1021/jacs.2c02764.10.1021/jacs.2c02764 ↗
83. Lee M, Kang B, Lee J, Lee J, Jung ST, Son CY, et al. De novo selected hACE2 mimics that integrate hotspot peptides with aptameric scaffolds for binding tolerance of SARS-CoV-2 variants. Sci Adv. 2022;8(43):eabq6207. https://doi.org/10.1126/sciadv.abq6207.10.1126/sciadv.abq6207 ↗
84. Yang M, Li C, Ye G, Shen C, Shi H, Zhong L, et al. Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity. Signal Transduct Target Ther. 2024;9(1):40. https://doi.org/10.1038/s41392-024-01748-w.10.1038/s41392-024-01748-w ↗
85. VanBlargan LA, Errico JM, Halfmann PJ, Zost SJ, Crowe JE Jr, Purcell LA, et al. An infectious SARS-CoV-2 B.1.1.529 omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat Med. 2022;28(3):490–5. https://doi.org/10.1038/s41591-021-01678-y.10.1038/s41591-021-01678-y ↗
86. Cerutti G, Guo Y, Wang P, Nair MS, Wang M, Huang Y, et al. Neutralizing antibody 5–7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain. Cell Rep. 2021;37(5): 109928. https://doi.org/10.1016/j.celrep.2021.109928.10.1016/j.celrep.2021.109928 ↗
87. Gong Y, Qin S, Dai L, Tian Z. The glycosylation in SARS-CoV-2 and its receptor ACE2. Signal Transduct Target Ther. 2021;6(1):396. https://doi.org/10.1038/s41392-021-00809-8.10.1038/s41392-021-00809-8 ↗
88. Campos D, Girgis M, Sanda M. Site-specific glycosylation of SARS-CoV-2: big challenges in mass spectrometry analysis. Proteomics. 2022;22(15–16): e2100322. https://doi.org/10.1002/pmic.202100322.10.1002/pmic.202100322 ↗
89. Li Y, Xu S, Ye Q, Chi H, Guo Z, Chen J, et al. Rational development of hypervalent glycan shield-binding nanoparticles with broad-spectrum inhibition against fatal viruses including SARS-CoV-2 variants. Adv Sci. 2023;10(2): 2202689. https://doi.org/10.1002/advs.202202689.10.1002/advs.202202689 ↗
90. Nakazawa D, Takeda Y, Kanda M, Tomaru U, Ogawa H, Kudo T, et al. Inhibition of toll-like receptor 4 and interleukin-1 receptor prevent SARS-CoV-2 mediated kidney injury. Cell Death Discov. 2023;9(1):293. https://doi.org/10.1038/s41420-023-01584-x.10.1038/s41420-023-01584-x ↗
91. Zhao Y, Kuang M, Li J, Zhu L, Jia Z, Guo X, et al. SARS-CoV-2 spike protein interacts with and activates Tlr41. Cell Res. 2021;31(7):818–20. https://doi.org/10.1038/s41422-021-00495-9.10.1038/s41422-021-00495-9 ↗
92. Aboudounya MM, Heads RJ. COVID-19 and toll-like receptor 4 (Tlr4): SARS-CoV-2 may bind and activate Tlr4 to increase ACE2 expression, facilitating entry and causing hyperinflammation. Mediat Inflamm. 2021;2021(1):8874339. https://doi.org/10.1155/2021/8874339.10.1155/2021/8874339 ↗
93. Junqueira C, Crespo A, Ranjbar S, de Lacerda LB, Lewandrowski M, Ingber J, et al. Fcgammar-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature. 2022;606(7914):576–84. https://doi.org/10.1038/s41586-022-04702-4.10.1038/s41586-022-04702-4 ↗
94. Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: their roles in pathogenesis. J Microbiol Immunol Infect. 2021;54(2):159–63. https://doi.org/10.1016/j.jmii.2020.03.022.10.1016/j.jmii.2020.03.022 ↗
95. Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582(7811):289–93. https://doi.org/10.1038/s41586-020-2223-y.10.1038/s41586-020-2223-y ↗
96. Bzówka M, Mitusińska K, Raczyńska A, Samol A, Tuszyński JA, Góra A. Structural and evolutionary analysis indicate that the SARS-CoV-2 Mpro is a challenging target for small-molecule inhibitor design. Int J Mol Sci. 2020;21(9):3099. https://doi.org/10.3390/ijms21093099.10.3390/ijms21093099 ↗
97. Savastano A, Ibanez de Opakua A, Rankovic M, Zweckstetter M. Nucleocapsid protein of SARS-CoV-2 phase separates into RNA-rich polymerase-containing condensates. Nat Commun. 2020;11(1):6041. https://doi.org/10.1038/s41467-020-19843-1.10.1038/s41467-020-19843-1 ↗
98. Chen K, Xiao F, Hu D, Ge W, Tian M, Wang W, et al. SARS-CoV-2 nucleocapsid protein interacts with RIG-I and represses RIG-mediated IFN-β production. Viruses. 2021;13(1):47. https://doi.org/10.3390/v13010047.10.3390/v13010047 ↗
99. Tong X, Tang R, Xu J, Wang W, Zhao Y, Yu X, et al. Liquid-liquid phase separation in tumor biology. Signal Transduct Target Ther. 2022;7(1):221. https://doi.org/10.1038/s41392-022-01076-x.10.1038/s41392-022-01076-x ↗
100. Wang B, Zhang L, Dai T, Qin Z, Lu H, Zhang L, et al. Liquid-liquid phase separation in human health and diseases. Signal Transduct Target Ther. 2021;6(1):290. https://doi.org/10.1038/s41392-021-00678-1.10.1038/s41392-021-00678-1 ↗